Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Section Editors
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
Editor's Choice
CARDIOVASCULAR PREVENTION / CLINICAL RESEARCH
The causal effects of placental weight on atherosclerotic cardiovascular disease: a Mendelian randomization and mediation analysis
1
Department of Hepatobiliary Surgery, Tianjin Medical University General Hospital, Tianjin, China
2
Department of Emergency, Tianjin Medical University General Hospital, Tianjin, China
3
Department of Critical Care Medicine, Tianjin Medical University General Hospital, Tianjin, China
These authors had equal contribution to this work
Submission date: 2024-08-08
Final revision date: 2024-09-24
Acceptance date: 2024-10-08
Online publication date: 2024-10-26
Corresponding author
Min Peng
Department of Critical Care Medicine, Tianjin Medical University, General Hospital, Tianjin 300052, China
Department of Critical Care Medicine, Tianjin Medical University, General Hospital, Tianjin 300052, China
Songtao Shou
Department of Emergency, Tianjin Medical University, General Hospital, Tianjin 300052, China
Department of Emergency, Tianjin Medical University, General Hospital, Tianjin 300052, China
Quanyan Liu
Department of Hepatobiliary Surgery, Tianjin Medical University, General Hospital, Tianjin 300052, China
Department of Hepatobiliary Surgery, Tianjin Medical University, General Hospital, Tianjin 300052, China
Arch Med Sci 2025;21(4):1141-1151
KEYWORDS
atherosclerotic cardiovascular diseaseplacental weightcoronary heart diseaseischemic strokemediation analysisMendelian randomization
TOPICS
ABSTRACT
Introduction:
Previous studies have linked placental weight (PW) to cardiovascular diseases, but the causality and potential mediators underlying this relationship are still unknown.
Material and methods:
We conducted Mendelian randomization (MR) analysis via summary statistics from genome-wide association studies (GWAS), including PW adjusted for sex, 21 candidate mediators and atherosclerotic cardiovascular disease (ASCVD), which includes coronary heart disease (CHD) and ischemic stroke (IS). Two-step MR was employed to identify and assess the mediation and proportion of potential mediators in the association between PW and ASCVD. Additionally, we conducted a repeated analysis using PW adjusted for gestational age and sex.
Results:
Univariable MR (UVMR) analysis revealed that for each 1-SD decrease in fetal genotype-determined PW adjusted for sex only, the risk of CHD increased by 24% (95% CI: 1.05–1.46) and the risk of large artery stroke (LAS) increased by 46% (95% CI: 1.13–1.89). Similar results were obtained in repeated analyses. The mediation MR analysis revealed that the causal relationship between fetal genotype-determined PW and CHD risk was primarily mediated by birthweight, type 2 diabetes, and education, each mediating 3.66% to 40.80% of the total effect. The causal relationship between fetal genotype-determined PW and LAS risk was mediated mainly by type 2 diabetes, which accounted for 22.11% of the total effect.
Conclusions:
This study identified a unidirectional causal relationship between lower PW and a greater ASCVD risk, with factors such as birthweight, type 2 diabetes, and education mediating the association between PW and ASCVD.
Previous studies have linked placental weight (PW) to cardiovascular diseases, but the causality and potential mediators underlying this relationship are still unknown.
Material and methods:
We conducted Mendelian randomization (MR) analysis via summary statistics from genome-wide association studies (GWAS), including PW adjusted for sex, 21 candidate mediators and atherosclerotic cardiovascular disease (ASCVD), which includes coronary heart disease (CHD) and ischemic stroke (IS). Two-step MR was employed to identify and assess the mediation and proportion of potential mediators in the association between PW and ASCVD. Additionally, we conducted a repeated analysis using PW adjusted for gestational age and sex.
Results:
Univariable MR (UVMR) analysis revealed that for each 1-SD decrease in fetal genotype-determined PW adjusted for sex only, the risk of CHD increased by 24% (95% CI: 1.05–1.46) and the risk of large artery stroke (LAS) increased by 46% (95% CI: 1.13–1.89). Similar results were obtained in repeated analyses. The mediation MR analysis revealed that the causal relationship between fetal genotype-determined PW and CHD risk was primarily mediated by birthweight, type 2 diabetes, and education, each mediating 3.66% to 40.80% of the total effect. The causal relationship between fetal genotype-determined PW and LAS risk was mediated mainly by type 2 diabetes, which accounted for 22.11% of the total effect.
Conclusions:
This study identified a unidirectional causal relationship between lower PW and a greater ASCVD risk, with factors such as birthweight, type 2 diabetes, and education mediating the association between PW and ASCVD.
REFERENCES (53)
1.
Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics – 2023 update: a report from the American Heart Association. Circulation 2023; 147: e93-621.
2.
Banach M, Kaźmierczak J, Mitkowski P, et al. Which patients at risk of cardiovascular disease might benefit the most from inclisiran? Polish experts’ opinion. The compromise between EBM and possibilities in healthcare. Arch Med Sci 2022; 18: 569-76.
3.
Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019. J Am Coll Cardiol 2020; 76: 2982-3021.
4.
Hasbani NR, Ligthart S, Brown MR, et al. American Heart Association’s Life’s Simple 7: lifestyle recommendations, polygenic risk, and lifetime risk of coronary heart disease. Circulation 2022; 145: 808-18.
5.
Dai X, Wiernek S, Evans JP, Runge MS. Genetics of coronary artery disease and myocardial infarction. World J Cardiol 2016; 8: 1-23.
6.
Fleming TP, Watkins AJ, Velazquez MA, et al. Origins of lifetime health around the time of conception: causes and consequences. Lancet 2018; 391: 1842-52.
7.
Hoffman DJ, Powell TL, Barrett ES, Hardy DB. Developmental origins of metabolic diseases. Physiol Rev 2021; 101: 739-95.
8.
Gluckman PD, Hanson MA, Cooper C, Thornburg KL. Effect of in utero and early-life conditions on adult health and disease. N Engl J Med 2008; 359: 61-73.
9.
Burton GJ, Fowden AL, Thornburg KL. Placental origins of chronic disease. Physiol Rev 2016; 96: 1509-65.
10.
Benirschke K, Burton GJ, Baergen RN. Pathology of the human placenta. Springer, Berlin Heidelberg 2012.
11.
Simpson RA, Mayhew TM, Barnes PR. From 13 weeks to term, the trophoblast of human placenta grows by the continuous recruitment of new proliferative units: a study of nuclear number using the disector. Placenta 1992; 13: 501-12.
12.
Burton GJ, Fowden AL. The placenta: a multifaceted, transient organ. Philos Trans R Soc B Biol Sci 2015; 370: 20140066.
13.
Lewis RM, Cleal JK, Godfrey KM. The placental role in developmental programming. In: Reproductive and Developmental Toxicology. Elsevier, 2022: 1325-38.
14.
Burton GJ, Jauniaux E. Pathophysiology of placental-derived fetal growth restriction. Am J Obstet Gynecol 2018; 218: S745-61.
15.
Matthiesen NB, Henriksen TB, Agergaard P, et al. Congenital heart defects and indices of placental and fetal growth in a nationwide study of 924 422 liveborn infants. Circulation 2016; 134: 1546-56.
16.
Barker DJP, Thornburg KL, Osmond C, Kajantie E, Eriksson JG. The surface area of the placenta and hypertension in the offspring in later life. Int J Dev Biol 2010; 54: 525-30.
17.
Barker DJ, Bull AR, Osmond C, Simmonds SJ. Fetal and placental size and risk of hypertension in adult life. BMJ 1990; 301: 259-62.
18.
Forsen T, Eriksson JG, Tuomilehto J, Osmond C, Barker DJP. Growth in utero and during childhood among women who develop coronary heart disease: longitudinal study. BMJ 1999; 319: 1403-7.
19.
Shaut CAE, Keene DR, Sorensen LK, Li DY, Stadler HS. HOXA13 is essential for placental vascular patterning and labyrinth endothelial specification. PLoS Genet 2008; 4: e1000073.
20.
Louey S, Jonker SS, Giraud GD, Thornburg KL. Placental insufficiency decreases cell cycle activity and terminal maturation in fetal sheep cardiomyocytes. J Physiol 2007; 580: 639-48.
21.
Morrison JL, Botting KJ, Dyer JL, Williams SJ, Thornburg KL, McMillen IC. Restriction of placental function alters heart development in the sheep fetus. Am J Physiol Regul Integr Comp Physiol 2007; 293: R306-13.
22.
Hagen ASE, Orbus RJ, Wilkening RB, Regnault TRH, Anthony RV. Placental expression of angiopoietin-1, angiopoietin-2 and Tie-2 during placental development in an ovine model of placental insufficiency-fetal growth restriction. Pediatr Res 2005; 58: 1228-32.
23.
Salafia CM, Charles AK, Maas EM. Placenta and Fetal Growth Restriction. Clin Obstet Gynecol 2006; 49: 236-56.
24.
Haavaldsen C, Samuelsen S, Eskild A. The association of maternal age with placental weight: a population-based study of 536 954 pregnancies. BJOG 2011; 118: 1470-6.
25.
Heshmati A, Koupil I. Placental weight and foetal growth rate as predictors of ischaemic heart disease in a Swedish cohort. J Develop Origins Health Dis 2014; 5: 164-70.
26.
Barker DJP, Thornburg KL. Placental programming of chronic diseases, cancer and lifespan: a review. Placenta 2013; 34: 841-5.
27.
Eriksson JG, Kajantie E, Thornburg KL, Osmond C, Barker DJP. Mother’s body size and placental size predict coronary heart disease in men. Eur Heart J 2011; 32: 2297-303.
28.
Martyn C, Barker D, Osmond C. Mothers’ pelvic size, fetal growth, and death from stroke and coronary heart disease in men in the UK. Lancet 1996; 348: 1264-8.
29.
Davies NM, Holmes MV, Smith GD. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ 2018; : k601.
30.
Lawlor DA. Commentary: two-sample Mendelian randomization: opportunities and challenges. Int J Epidemiol 2016; 45: 908-15.
31.
Relton CL, Davey Smith G. Two-step epigenetic Mendelian randomization: a strategy for establishing the causal role of epigenetic processes in pathways to disease. Int J Epidemiol 2012; 41: 161-76.
32.
Burgess S, Thompson SG. Multivariable mendelian randomization: the use of pleiotropic genetic variants to estimate causal effects. Am J Epidemiol 2015; 181: 251-60.
33.
Sanderson E, Smith GD, Windmeijer F, Bowden J. An examination of multivariable Mendelian randomization in the single-sample and two-sample summary data settings. Int J Epidemiol 2019; 48: 713-27.
34.
Skrivankova VW, Richmond RC, Woolf BAR, et al. Strengthening the reporting of observational studies in epidemiology using mendelian randomisation (STROBE-MR): explanation and elaboration. BMJ 2021; 375: n2233.
35.
Beaumont RN, Flatley C, Vaudel M, et al. Genome-wide association study of placental weight identifies distinct and shared genetic influences between placental and fetal growth. Nat Genet 2023; 55: 1807-19.
36.
Nikpay M, Goel A, Won HH, et al.; the CARDIoGRAMplusC4D Consortium. A comprehensive 1000 Genomes-based genome-wide association meta-analysis of coronary artery disease. Nat Genet 2015; 47: 1121-30.
37.
Malik R, Chauhan G, Traylor M, et al. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. Nat Genet 2018; 50: 524-37.
38.
Adams HP, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24: 35-41.
39.
Lawlor DA, Harbord RM, Sterne JAC, Timpson N, Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med 2008; 27: 1133-63.
40.
Carter AR, Sanderson E, Hammerton G, et al. Mendelian randomisation for mediation analysis: current methods and challenges for implementation. Eur J Epidemiol 2021; 36: 465-78.
41.
Burgess S, Bowden J, Fall T, Ingelsson E, Thompson SG. Sensitivity analyses for robust causal inference from mendelian randomization analyses with multiple genetic variants. Epidemiology 2017; 28: 30-42.
42.
Bowden J, Smith GD, Haycock PC, Burgess S. Consistent estimation in mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol 2016; 40: 304-14.
43.
Hartwig FP, Smith GD, Bowden J. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. Int J Epidemiol 2017; 46: 1985-98.
44.
Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet 2018; 50: 693-8.
45.
Xue H, Shen X, Pan W. Constrained maximum likelihood-based Mendelian randomization robust to both correlated and uncorrelated pleiotropic effects. Am J Human Genet 2021; 108: 1251-69.
46.
Rees JMB, Wood AM, Burgess S. Extending the MR-Egger method for multivariable Mendelian randomization to correct for both measured and unmeasured pleiotropy. Stat Med 2017; 36: 4705-18.
47.
Markus HS, De Leeuw FE. Cerebral small vessel disease: recent advances and future directions. Int J Stroke 2023; 18: 4-14.
48.
Khan U, Porteous L, Hassan A, Markus HS. Risk factor profile of cerebral small vessel disease and its subtypes. J Neurol Neurosurg Psychiatry 2006; 78: 702-6.
49.
Ardissino M, Morley AP, Slob EAW, et al. Birth weight influences cardiac structure, function, and disease risk: evidence of a causal association. Eur Heart J 2024; 45: 443-54.
50.
Kong L, Wang Y, Ye C, et al. Opposite causal effects of birthweight on myocardial infarction and atrial fibrillation and the distinct mediating pathways: a mendelian randomization study. Cardiovasc Diabetol 2023; 22: 338.
51.
Forsen T, Eriksson JG, Tuomilehto J, Teramo K, Osmond C, Barker DJP. Mother’s weight in pregnancy and coronary heart disease in a cohort of finnish men: follow up study. BMJ 1997; 315: 837-40.
52.
Hughes AE, Hattersley AT, Flanagan SE, Freathy RM. Two decades since the fetal insulin hypothesis: what have we learned from genetics? Diabetologia 2021; 64: 717-26.
53.
Emdin CA, Khera AV, Kathiresan S. Mendelian randomization. JAMA 2017; 318: 1925-6.
Share
RELATED ARTICLE
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
